Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

The recent decision by the Supreme Court of India allowing withdrawal of life support for a 32-year-old man in an irreversible permanent vegetative state is an important development in patient-centered healthcare.

The order follows the principles established in the landmark Common Cause v. Union of India, which recognized passive euthanasia and affirmed that individuals have the right to die with dignity. From the perspective of a critical care specialist, this decision supports ethical medical practice while protecting the dignity and rights of patients.

In modern intensive care units (ICUs), doctors use advanced technologies such as ventilators, feeding tubes, dialysis machines, and strong medications to sustain life during serious illness. These treatments are extremely valuable when there is a reasonable chance of recovery.

However, in some medical conditions—particularly severe brain injuries—patients may enter a permanent vegetative state. In this condition, the patient’s body may continue functioning with medical support, but the brain has lost the ability to produce consciousness or awareness. The patient cannot communicate, recognize loved ones, or interact with the environment, and medical science currently has no effective treatment to reverse this condition.

From a medical standpoint, continuing life support in such cases may only prolong biological survival without any possibility of recovery or meaningful quality of life. The Supreme Court’s decision acknowledges this difficult reality and allows withdrawal of life-sustaining treatment when doctors confirm that recovery is medically impossible. This approach respects the patient’s dignity and avoids unnecessary prolongation of suffering.

Harish Rana Case: Key benefits

One of the key benefits of this judgment is the recognition of dignity at the end of life. The Court has interpreted the right to life under the Constitution of India to include the right to die with dignity. In practical terms, this means that patients should not be forced to remain on life-support machines when such treatment no longer benefits them.

Medicine should focus not only on prolonging life but also on ensuring that patients are treated with respect, comfort, and compassion during their final stages of life.

The decision also supports patient autonomy, which is a core principle of ethical medical care. Individuals have the right to make decisions about their own bodies and medical treatment. The recognition of living wills or advance directives allows patients to express their wishes in advance regarding life-prolonging treatments. This ensures that medical decisions align with the patient’s values and preferences, even if the patient is no longer able to communicate.

Also read: Harish Rana Case Highlights Why Planning For A Living Will Is Important

Another important benefit is the support it provides to families. Families often experience deep emotional stress when a loved one remains in a permanent vegetative state for a long period. They may struggle with uncertainty about whether continuing life support is truly helping the patient.

The Supreme Court’s framework provides a clear and compassionate process for decision-making involving medical boards and proper documentation. This helps families make informed choices in consultation with doctors while ensuring that the decision is ethically and legally sound.

Harish Rana Case: Offers Clarity For Healthcare Workers

The ruling also offers legal clarity for doctors and hospitals. In the past, physicians sometimes feared legal consequences if life support was withdrawn, even in medically futile situations.

The guidelines established under the Common Cause judgment create a structured and transparent process for making such decisions. This allows doctors to practice responsible and ethical medicine without unnecessary legal concerns.

Also read: Passive Euthanasia: Harish Rana’s Case May Reshape End-of-life Protocols, Say Experts

Passive Euthanasia: A Compassionate Step

In conclusion, the Supreme Court’s order is a compassionate step forward in Indian healthcare. From a critical care perspective, it respects patient dignity, supports family decision-making, provides legal clarity for doctors, and encourages thoughtful end-of-life care.

Most importantly, it reminds us that the true goal of medicine is not merely to extend life at all costs, but to ensure that every patient is treated with dignity, humanity, and respect throughout all stages of life.

Also read: Harish Rana Case Brings Spotlight On How Passive Euthanasia Has Evolved Over The Years

Amid a global increase in multidrug resistance, the World Health Organization (WHO) has released new guidelines that flags the lack of innovative antibiotics for vulnerable populations, as well as press the need for the rapid development of drugs to target three deadly bacterial infections.

The WHO's 2025 report on antibacterials in pipeline has highlighted that 90 new antibacterial agents are in preclinical or clinical development. Yet few are innovative antibiotic candidates with potential to target bacterial priority pathogens.

The WHO-developed Target Product Profiles (TPPs) call for accelerating the development of antibiotics to tackle the burden of drug-resistant bacteria in at-risk populations worldwide that lead to:

• Severe multidrug-resistant gram-negative infections such as bloodstream infections and hospital-acquired or ventilator-associated bacterial pneumonia. These are caused by carbapenem-resistant Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa.

• Severe antibiotic-resistant gram-positive infections in immune-suppressed and critically ill patients. It is caused by Enterococcus faecium
• Community-acquired and health care-associated bacterial meningitis -- a devastating and deadly disease that not only accelerates fatality rate but also causes long-term disabilities, including hearing loss, epilepsy or cognitive impairment.

“The scientific community has developed and approved new antibiotics in recent years. This is good, but unfortunately not sufficient to catch up with evolving drug-resistant bacteria, especially against those of greatest concern,” said Dr Yvan Hutin, Director of Antimicrobial Resistance at WHO.

"We need a reliable pipeline with new antibacterial agents that are innovative, affordable, and accessible to all those who need them.”

The TPPs have been developed with extensive global consultation and also define the minimum and preferred characteristics of future antibacterials against these diseases, which specifically increase the risk of immunosuppressed people and critically ill patients. The vulnerable populations are also at risk of more deaths, prolonged hospitalizations and increased demand for intensive care that in turn strains health care systems.

What The TPPs Seek

The TPPs share a blueprint which:

• prioritizes developing antibiotics for infections with high morbidity and mortality
• sets specific standards for quality, efficacy, safety, and pharmacokinetics
• includes diverse and vulnerable populations, including immunosuppressed patients, critically ill patients, neonates, and children
• promotes partnerships between public and private sector

Rising Global Antimicrobial Resistance

Antimicrobial resistance (AMR) occurs when germs develop the ability to defeat the drugs designed to kill them.

It is one of the 10 top global health threats, undermining the effectiveness of essential treatments and placing millions at risk of untreatable infections.

As per WHO data, AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019.

In the US alone, more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result, according to CDC's 2019 Antibiotic Resistance (AR) Threats Report.

The WHO in a 2025 report noted that one in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments.

Between 2018 and 2023, antibiotic resistance rose in over 40 percent of the monitored antibiotics with an average annual increase of 5-15 percent.

About 13 people, including a 3-year-old child, have died in East Godavari district of Andhra Pradesh in recent days, allegedly after consuming adulterated milk.

Dozens more are hospitalized and receiving treatment at hospitals in Rajamahendravaram, according to PTI news agency.

The cases first came to light on February 22, when several elderly residents were admitted to hospitals with symptoms such as anuria (absence of urine production), vomiting, abdominal pain, and kidney failure, requiring dialysis.

"The death toll in the suspected milk adulteration case in East Godavari district has reached 13, while seven persons are undergoing treatment at hospitals in Rajamahendravaram," health officials said.

Action Taken

Primary investigations indicated milk adulteration as the major reason behind the cases. High blood urea and serum creatinine levels in medical examinations of the victims also suggested possible toxic exposure.

The contaminated milk was reportedly supplied to nearly 106 families by Varalakshmi Milk Dairy in Narasapuram village of Korukonda mandal. Following the cases, the supply was immediately halted, the report said.

To curb further fatalities and hospitalization, officials have set up emergency medical camps in affected localities, with doctors and ambulances deployed round the clock.

The suspected milk vendor, Addala Ganeswararao (33), a resident of Narasapuram village, has also been taken into custody, and the associated dairy unit has been sealed.

The state Food Safety Department also plans to distribute pamphlets and booklets in educational institutions to raise awareness about identifying adulterated milk.

Recent Cases Of Contaminated Food In India

Earlier this month, the Uttar Pradesh Food Safety and Drug Administration (UPFSDA) issued 37 notices for non-compliance to sellers of substandard oil. The department also seized oil worth Rs. 6.43 crore.

Additionally, the FSSAI seized fake paneer near Noida, 1,400 kg of fake khoya in Jhansi, and 400 kg of expired ghee.

Health and Me had previously reported on FSSAI raids in Kanpur, where adulterated oil, rotten dates, and sweets were found. Bacteria were found in Amul milk packages, along with Mother Dairy and Country Delight.

Also read: FSSAI Reveals Key Tips To Keep Your Kitchen Healthy – How To Spot High Quality Vegetables?

FSSAI In Action

In February, the FSSAI launches a nationwide adulteration drive to curb adulteration in sweets, milk products, edible oils, and other festive foods.

The food regulator also led intensive inspections and on-the-spot testing through Food Safety on Wheels across States/UT.

Fisheries, Animal Husbandry, and Dairying Minister Rajiv Ranjan Singh today informed the Lok Sabha about action taken by FSSAI against the violators during 2025-26.

"A total of 1,65,747 samples were analyzed by the FSSAI between 2025-26. Of these, 28,450 were found non-conforming, with 6492 unsafe and 19,073 in the sub-standard category," Singh told the Parliament.

During the period, a total of 2,493 samples were analyzed in Andhra Pradesh. Of these, 216 were found non-conforming, with 101 in the 'unsafe' and 114 'sub-standard' category.